None
Quote | Addex Pharms Ltd Ord (OTCMKTS:ADDXF)
Last: | $0.99 |
---|---|
Change Percent: | 0.0% |
Open: | $0.99 |
Close: | $0.99 |
High: | $0.99 |
Low: | $0.99 |
Volume: | 100 |
Last Trade Date Time: | 02/03/2022 04:53:25 pm |
News | Addex Pharms Ltd Ord (OTCMKTS:ADDXF)
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April ...
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing ...
Message Board Posts | Addex Pharms Ltd Ord (OTCMKTS:ADDXF)
Subject | By | Source | When |
---|---|---|---|
Van Leeuwenhoeck Issues Initiation of Coverage Research Report | tykundegex | investorshub | 10/18/2017 1:33:53 PM |
Addex Awarded $5.3 Million Grant from US National | tykundegex | investorshub | 10/18/2017 1:21:16 PM |
IMO, Addex has a decent possibility of a | tykundegex | investorshub | 06/08/2016 7:35:22 PM |
Orphan designation granted for Dipraglurant! Next up, | tykundegex | investorshub | 01/05/2016 1:37:58 AM |
Shares up a little on 15x volume because | tykundegex | investorshub | 08/14/2015 1:33:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Addex Pharms Ltd Ord Company Name:
ADDXF Stock Symbol:
OTCMKTS Market:
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April ...
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing ...
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO a...